111, Inc. Forms Special Committee to Evaluate Buyout Proposal

The newly established committee is chaired by Jian Sun, joined by fellow independent directors Nee Chuan Teo and Jun Luo. Their mandate is to scrutinize the preliminary proposal and weigh it against other strategic paths available to the digital healthcare operator. Despite the formation of this panel, the company’s board emphasized that no formal decisions have been reached, and there is no guarantee that the current discussions will culminate in a definitive agreement or any specific transaction.

Investors are advised that the company remains under no obligation to provide updates on these deliberations unless required by regulatory statutes. 111, Inc. continues to operate its integrated digital ecosystem, which includes the 1 Pharmacy retail site and the 1 Medicine B2B sourcing platform, while maintaining its focus on AI-driven pharmaceutical supply chain services.